Business Description
Molecure SA
ISIN : PLONCTH00011
Compare
Compare
Traded in other countries / regions
MOC.Poland1B1.Germany IPO Date
2018-04-19Description
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.14 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.31 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Book Growth Rate | -4.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.38 | |||||
| 9-Day RSI | 38.09 | |||||
| 14-Day RSI | 34.6 | |||||
| 6-1 Month Momentum % | -4.83 | |||||
| 12-1 Month Momentum % | -17.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.81 | |||||
| Quick Ratio | 8.81 | |||||
| Cash Ratio | 8.34 | |||||
| Days Payable | 1742.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.2 | |||||
| Shareholder Yield % | -0.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -17.78 | |||||
| ROA % | -16.26 | |||||
| ROIC % | -29.42 | |||||
| 3-Year ROIIC % | -127.81 | |||||
| ROC (Joel Greenblatt) % | -220.86 | |||||
| ROCE % | -17.02 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 61.18 | |||||
| PB Ratio | 2.19 | |||||
| Price-to-Tangible-Book | 5.67 | |||||
| EV-to-EBIT | -7.37 | |||||
| EV-to-EBITDA | -8.44 | |||||
| EV-to-FCF | -2.53 | |||||
| Price-to-Net-Current-Asset-Value | 7.75 | |||||
| Price-to-Net-Cash | 8.3 | |||||
| Earnings Yield (Greenblatt) % | -13.56 | |||||
| FCF Yield % | -34.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecure SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | |||
| EPS (TTM) (zł) | -1.4 | ||
| Beta | 1.99 | ||
| Volatility % | 31.31 | ||
| 14-Day RSI | 34.6 | ||
| 14-Day ATR (zł) | 0.574875 | ||
| 20-Day SMA (zł) | 10.9085 | ||
| 12-1 Month Momentum % | -17.07 | ||
| 52-Week Range (zł) | 9.67 - 22.5 | ||
| Shares Outstanding (Mil) | 16.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecure SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecure SA Stock Events
| Event | Date | Price(zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecure SA Frequently Asked Questions
What is Molecure SA(WAR:MOC)'s stock price today?
The current price of WAR:MOC is zł10.38. The 52 week high of WAR:MOC is zł22.50 and 52 week low is zł9.67.
When is next earnings date of Molecure SA(WAR:MOC)?
The next earnings date of Molecure SA(WAR:MOC) is .
Does Molecure SA(WAR:MOC) pay dividends? If so, how much?
Molecure SA(WAR:MOC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers